Browse LMTK2

Summary
SymbolLMTK2
Namelemur tyrosine kinase 2
Aliases KIAA1079; KPI2; KPI-2; cprk; LMR2; BREK; AATYK2; PPP1R100; protein phosphatase 1, regulatory subunit 100; CD ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Multi-pass membrane protein
Domain PF07714 Protein tyrosine kinase
Function

Phosphorylates PPP1C, phosphorylase b and CFTR.

> Gene Ontology
 
Biological Process GO:0000041 transition metal ion transport
GO:0001881 receptor recycling
GO:0006826 iron ion transport
GO:0007034 vacuolar transport
GO:0015682 ferric iron transport
GO:0016197 endosomal transport
GO:0016482 cytosolic transport
GO:0018105 peptidyl-serine phosphorylation
GO:0018107 peptidyl-threonine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0018210 peptidyl-threonine modification
GO:0032456 endocytic recycling
GO:0033572 transferrin transport
GO:0043112 receptor metabolic process
GO:0045022 early endosome to late endosome transport
GO:0046777 protein autophosphorylation
GO:0072512 trivalent inorganic cation transport
GO:0098927 vesicle-mediated transport between endosomal compartments
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004857 enzyme inhibitor activity
GO:0004864 protein phosphatase inhibitor activity
GO:0017022 myosin binding
GO:0019208 phosphatase regulator activity
GO:0019212 phosphatase inhibitor activity
GO:0019888 protein phosphatase regulator activity
GO:0070853 myosin VI binding
Cellular Component GO:0005769 early endosome
GO:0055037 recycling endosome
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolLMTK2
Namelemur tyrosine kinase 2
Aliases KIAA1079; KPI2; KPI-2; cprk; LMR2; BREK; AATYK2; PPP1R100; protein phosphatase 1, regulatory subunit 100; CD ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LMTK2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolLMTK2
Namelemur tyrosine kinase 2
Aliases KIAA1079; KPI2; KPI-2; cprk; LMR2; BREK; AATYK2; PPP1R100; protein phosphatase 1, regulatory subunit 100; CD ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LMTK2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolLMTK2
Namelemur tyrosine kinase 2
Aliases KIAA1079; KPI2; KPI-2; cprk; LMR2; BREK; AATYK2; PPP1R100; protein phosphatase 1, regulatory subunit 100; CD ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LMTK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3430.11
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6660.558
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1080.897
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2960.238
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4360.849
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1190.968
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2850.412
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2980.836
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.310.842
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3490.689
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0030.998
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0320.703
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LMTK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLMTK2
Namelemur tyrosine kinase 2
Aliases KIAA1079; KPI2; KPI-2; cprk; LMR2; BREK; AATYK2; PPP1R100; protein phosphatase 1, regulatory subunit 100; CD ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LMTK2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLMTK2
Namelemur tyrosine kinase 2
Aliases KIAA1079; KPI2; KPI-2; cprk; LMR2; BREK; AATYK2; PPP1R100; protein phosphatase 1, regulatory subunit 100; CD ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LMTK2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LMTK2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLMTK2
Namelemur tyrosine kinase 2
Aliases KIAA1079; KPI2; KPI-2; cprk; LMR2; BREK; AATYK2; PPP1R100; protein phosphatase 1, regulatory subunit 100; CD ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LMTK2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLMTK2
Namelemur tyrosine kinase 2
Aliases KIAA1079; KPI2; KPI-2; cprk; LMR2; BREK; AATYK2; PPP1R100; protein phosphatase 1, regulatory subunit 100; CD ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LMTK2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLMTK2
Namelemur tyrosine kinase 2
Aliases KIAA1079; KPI2; KPI-2; cprk; LMR2; BREK; AATYK2; PPP1R100; protein phosphatase 1, regulatory subunit 100; CD ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LMTK2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLMTK2
Namelemur tyrosine kinase 2
Aliases KIAA1079; KPI2; KPI-2; cprk; LMR2; BREK; AATYK2; PPP1R100; protein phosphatase 1, regulatory subunit 100; CD ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LMTK2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.